These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

464 related items for PubMed ID: 29249606

  • 21. Generation of Monoclonal Antibodies against Dengue Virus Type 4 and Identification of Enhancing Epitopes on Envelope Protein.
    Tang CT, Liao MY, Chiu CY, Shen WF, Chiu CY, Cheng PC, Chang GJ, Wu HC.
    PLoS One; 2015; 10(8):e0136328. PubMed ID: 26309127
    [Abstract] [Full Text] [Related]

  • 22. Transplantation of a quaternary structure neutralizing antibody epitope from dengue virus serotype 3 into serotype 4.
    Widman DG, Young E, Nivarthi U, Swanstrom JA, Royal SR, Yount BL, Debbink K, Begley M, Marcet S, Durbin A, de Silva AM, Messer WB, Baric RS.
    Sci Rep; 2017 Dec 07; 7(1):17169. PubMed ID: 29215033
    [Abstract] [Full Text] [Related]

  • 23. Identification of a novel infection-enhancing epitope on dengue prM using a dengue cross-reacting monoclonal antibody.
    Luo YY, Feng JJ, Zhou JM, Yu ZZ, Fang DY, Yan HJ, Zeng GC, Jiang LF.
    BMC Microbiol; 2013 Aug 29; 13():194. PubMed ID: 23987307
    [Abstract] [Full Text] [Related]

  • 24. Identification of Dengue Virus Serotype 3 Specific Antigenic Sites Targeted by Neutralizing Human Antibodies.
    Young E, Carnahan RH, Andrade DV, Kose N, Nargi RS, Fritch EJ, Munt JE, Doyle MP, White L, Baric TJ, Stoops M, DeSilva A, Tse LV, Martinez DR, Zhu D, Metz S, Wong MP, Espinosa DA, Montoya M, Biering SB, Sukulpolvi-Petty S, Kuan G, Balmaseda A, Diamond MS, Harris E, Crowe JE, Baric RS.
    Cell Host Microbe; 2020 May 13; 27(5):710-724.e7. PubMed ID: 32407709
    [Abstract] [Full Text] [Related]

  • 25. Combinatorial Resurfacing of Dengue Envelope Protein Domain III Antigens Selectively Ablates Epitopes Associated with Serotype-Specific or Infection-Enhancing Antibody Responses.
    Remmel JL, Beauchemin KS, Mishra AK, Frei JC, Lai JR, Bailey-Kellogg C, Ackerman ME.
    ACS Comb Sci; 2020 Sep 14; 22(9):446-456. PubMed ID: 32574486
    [Abstract] [Full Text] [Related]

  • 26. An Epitope-Substituted DNA Vaccine Improves Safety and Immunogenicity against Dengue Virus Type 2.
    Tang CT, Li PC, Liu IJ, Liao MY, Chiu CY, Chao DY, Wu HC.
    PLoS Negl Trop Dis; 2015 Sep 14; 9(7):e0003903. PubMed ID: 26135599
    [Abstract] [Full Text] [Related]

  • 27. High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection.
    Tsai WY, Lai CY, Wu YC, Lin HE, Edwards C, Jumnainsong A, Kliks S, Halstead S, Mongkolsapaya J, Screaton GR, Wang WK.
    J Virol; 2013 Dec 14; 87(23):12562-75. PubMed ID: 24027331
    [Abstract] [Full Text] [Related]

  • 28. The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein.
    VanBlargan LA, Mukherjee S, Dowd KA, Durbin AP, Whitehead SS, Pierson TC.
    PLoS Pathog; 2013 Dec 14; 9(12):e1003761. PubMed ID: 24348242
    [Abstract] [Full Text] [Related]

  • 29. Identification of an epitope on the dengue virus membrane (M) protein defined by cross-protective monoclonal antibodies: design of an improved epitope sequence based on common determinants present in both envelope (E and M) proteins.
    Falconar AK.
    Arch Virol; 1999 Dec 14; 144(12):2313-30. PubMed ID: 10664386
    [Abstract] [Full Text] [Related]

  • 30. Antibody with an engineered Fc region as a therapeutic agent against dengue virus infection.
    Ramadhany R, Hirai I, Sasaki T, Ono K, Ramasoota P, Ikuta K, Kurosu T.
    Antiviral Res; 2015 Dec 14; 124():61-8. PubMed ID: 26522769
    [Abstract] [Full Text] [Related]

  • 31. Genotype-specific neutralization and protection by antibodies against dengue virus type 3.
    Brien JD, Austin SK, Sukupolvi-Petty S, O'Brien KM, Johnson S, Fremont DH, Diamond MS.
    J Virol; 2010 Oct 14; 84(20):10630-43. PubMed ID: 20702644
    [Abstract] [Full Text] [Related]

  • 32. Analysis of Individuals from a Dengue-Endemic Region Helps Define the Footprint and Repertoire of Antibodies Targeting Dengue Virus 3 Type-Specific Epitopes.
    Andrade DV, Katzelnick LC, Widman DG, Balmaseda A, de Silva AM, Baric RS, Harris E.
    mBio; 2017 Sep 19; 8(5):. PubMed ID: 28928210
    [Abstract] [Full Text] [Related]

  • 33. Eliciting cross-neutralizing antibodies in mice challenged with a dengue virus envelope domain III expressed in Escherichia coli.
    Yang J, Zhang J, Chen W, Hu Z, Zhu J, Fang X, Yuan W, Li M, Hu X, Tan Y, Hu F, Rao X.
    Can J Microbiol; 2012 Apr 19; 58(4):369-80. PubMed ID: 22420529
    [Abstract] [Full Text] [Related]

  • 34. [Mapping of the B Cell Neutralizing Epitopes on ED III of Envelope Protein from Dengue Virus].
    Lin Y, Wen K, Guo Y, Qiu L, Pan Y, Yu L, Di B, Chen Y.
    Bing Du Xue Bao; 2015 Nov 19; 31(6):665-73. PubMed ID: 26951013
    [Abstract] [Full Text] [Related]

  • 35. Epitope resurfacing on dengue virus-like particle vaccine preparation to induce broad neutralizing antibody.
    Shen WF, Galula JU, Liu JH, Liao MY, Huang CH, Wang YC, Wu HC, Liang JJ, Lin YL, Whitney MT, Chang GJ, Chen SR, Wu SR, Chao DY.
    Elife; 2018 Oct 18; 7():. PubMed ID: 30334522
    [Abstract] [Full Text] [Related]

  • 36. Dengue virus antibody database: Systematically linking serotype-specificity with epitope mapping in dengue virus.
    Chaudhury S, Gromowski GD, Ripoll DR, Khavrutskii IV, Desai V, Wallqvist A.
    PLoS Negl Trop Dis; 2017 Feb 18; 11(2):e0005395. PubMed ID: 28222130
    [Abstract] [Full Text] [Related]

  • 37. Potent dengue virus neutralization by a therapeutic antibody with low monovalent affinity requires bivalent engagement.
    Edeling MA, Austin SK, Shrestha B, Dowd KA, Mukherjee S, Nelson CA, Johnson S, Mabila MN, Christian EA, Rucker J, Pierson TC, Diamond MS, Fremont DH.
    PLoS Pathog; 2014 Apr 18; 10(4):e1004072. PubMed ID: 24743696
    [Abstract] [Full Text] [Related]

  • 38. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica.
    Roehrig JT, Bolin RA, Kelly RG.
    Virology; 1998 Jul 05; 246(2):317-28. PubMed ID: 9657950
    [Abstract] [Full Text] [Related]

  • 39. Anti-Chikungunya Virus Monoclonal Antibody That Inhibits Viral Fusion and Release.
    Tumkosit U, Siripanyaphinyo U, Takeda N, Tsuji M, Maeda Y, Ruchusatsawat K, Shioda T, Mizushima H, Chetanachan P, Wongjaroen P, Matsuura Y, Tatsumi M, Tanaka A.
    J Virol; 2020 Sep 15; 94(19):. PubMed ID: 32699087
    [Abstract] [Full Text] [Related]

  • 40. Beyond Neutralizing Antibody Levels: The Epitope Specificity of Antibodies Induced by National Institutes of Health Monovalent Dengue Virus Vaccines.
    Swanstrom JA, Nivarthi UK, Patel B, Delacruz MJ, Yount B, Widman DG, Durbin AP, Whitehead SS, De Silva AM, Baric RS.
    J Infect Dis; 2019 Jun 19; 220(2):219-227. PubMed ID: 30895307
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.